ADA 2019—Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.
Daily aspirin for primary prevention of heart disease is a practice under scrutiny. Based on the new 2019 ACC/AHA CVD prevention guidelines, is this patient a candidate?
Test your knowledge of the key elements and outcomes of the highly buzzed about REDUCE-IT trial with this 5-question quiz.
How much do you know about the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease? Take this 9-question quiz to find out.
Man's need for exercise began with foraging for subsistence and is just as essential in our age of sitting and screen time. Trace the evolution, here.
Eighty percent of all cardiovascular events are preventable. The ACC/AHA 2019 guidelines are a single source of best practices to help achieve that goal. Review them here, at-a-glance.
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
What approach is now AHA/ACC guideline-recommended for a patient with primary hypercholesterolemia, with an LDL-C of 192 mg/dL? Take Quiz #3.
How will changes in the AHA/ACC update to the 2013 guidelines help optimize care for patients with ASCVD? Try part 2 of our 3-part quiz and find out.